Chinese conglomerate Sanpower Group Co Ltd recently acquired Valeant Pharmaceuticals International Inc’s Dendreon business for around $819.9 million, far more than the $300 million Valeant paid when it bought it out of bankruptcy in 2015.
Related Articles
Generic-Drug Price Fixing: Is It Happening?
It started with an inhaler. Like many of you, I am a rheumatologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…
Docs & Patients Should Remember to Use Generics
(Reuters Health)—Prescribing generic medicines instead of brand name drugs whenever possible cuts costs, improves patient adherence and improves health outcomes, according to a new recommendation from the American College of Physicians. “Generic medications are cheaper and patients are more likely to get those prescriptions filled,” says Dr. Amir Qaseem of the American College of Physicians,…
Hamstrung by Red Tape, Hospital Operators Buy Their Way into India
NEW DELHI (Reuters)—For nearly two years, Parkway Pantai has delayed the opening of its 450-bed India hospital, the Singapore-based medical firm’s bid to cash in on one of Asia’s fastest growing private healthcare markets, as it waited for the necessary permits. Parkway, a unit of the world’s second largest healthcare group by market value IHH…
Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…